Loading...
XPARAMPLI
Market cap156mUSD
Dec 24, Last price  
3.12EUR
1D
-1.26%
1Q
-4.85%
Jan 2017
-17.59%
IPO
-35.92%
Name

Amplitude Surgical SA

Chart & Performance

D1W1MN
XPAR:AMPLI chart
P/E
97.95
P/S
1.41
EPS
0.03
Div Yield, %
0.00%
Shrs. gr., 5y
0.07%
Rev. gr., 5y
0.67%
Revenues
106m
+5.81%
047,249,00050,268,00058,228,00071,090,00080,788,00093,356,000100,336,000102,559,00088,286,00082,713,00087,559,000100,200,000106,019,000
Net income
2m
-96.11%
-2,266,000-2,017,000-2,149,000-2,846,000-17,646,000219,000-12,052,000-9,446,000-8,989,000-14,198,000-14,099,000-4,392,00039,246,0001,528,000
CFO
4m
-50.06%
-3,399,000-3,264,000197,000-1,953,000-16,530,0001,987,0002,680,0008,981,0008,242,00012,384,0002,344,0007,983,0008,096,0004,043,000
Earnings
Mar 18, 2025

Profile

Amplitude Surgical SA develops and markets products for orthopedic surgery. The company provides a range of orthopedic products for primary and revision surgery aimed at treating pathologies of the hip, knee, and lower extremities primarily for foot and ankle surgery. It offers knee and hip prostheses and implants for the foot and ankle. The company also provides AMPLIVISION, a computer-assisted surgical system; the i.M.A.G.E., a single-use made-to-measure instrument system; and the E.T.O.I.L.E, a technology platform for anterior approaches resulting in less-invasive surgery. In addition, it offers instruments for fitting implants. The company sells its products through a network of distributors and agents in approximately 30 countries. It serves patients, surgeons, and healthcare facilities. Amplitude Surgical SA was founded in 1997 and is headquartered in Valence, France.
URL
https://www.amplitude-surgical.com/
IPO date
Jun 26, 2015
Employees
489
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
106,019
5.81%
100,200
14.44%
87,559
5.86%
Cost of revenue
87,301
69,483
64,738
Unusual Expense (Income)
NOPBT
18,718
30,717
22,821
NOPBT Margin
17.66%
30.66%
26.06%
Operating Taxes
(455)
489
894
Tax Rate
1.59%
3.92%
NOPAT
19,173
30,228
21,927
Net income
1,528
-96.11%
39,246
-993.58%
(4,392)
-68.85%
Dividends
Dividend yield
Proceeds from repurchase of equity
(59)
(501)
457
BB yield
0.04%
0.31%
-0.34%
Debt
Debt current
15,228
11,233
11,728
Long-term debt
114,862
95,224
127,335
Deferred revenue
6,111
5,828
Other long-term liabilities
32,417
31,927
34,028
Net debt
100,988
68,536
117,552
Cash flow
Cash from operating activities
4,043
8,096
7,983
CAPEX
(18,935)
(19,394)
(12,142)
Cash from investing activities
(14,422)
45,544
(12,412)
Cash from financing activities
2,483
(37,434)
(5,409)
FCF
7,261
41,835
21,484
Balance
Cash
29,101
37,212
21,043
Long term investments
1,000
709
468
Excess cash
23,801
32,911
17,133
Stockholders' equity
2,008
(11,616)
(94,587)
Invested Capital
243,469
245,219
319,818
ROIC
7.85%
10.70%
6.77%
ROCE
7.56%
13.05%
10.06%
EV
Common stock shares outstanding
47,971
48,021
48,021
Price
3.36
1.20%
3.32
17.73%
2.82
27.03%
Market cap
161,183
1.10%
159,430
17.73%
135,419
27.60%
EV
262,171
227,966
255,273
EBITDA
30,573
43,691
35,588
EV/EBITDA
8.58
5.22
7.17
Interest
10,115
12,331
13,623
Interest/NOPBT
54.04%
40.14%
59.70%